F-0017

N/A

Report date: 2025/01/26 18:00:33

NME

Base Information

Drug NameF-0017

Drug Alias NameKRAS-Targeting siRNA (Nitto BioPharma)ND-05-1192 lipid nanoparticle (Nitto BioPharma)NBP-1192 lipid nanoparticle (Nitto BioPharma)F-0017

ClassificationSmall molecules > LipidSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA

Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors

TargetsGTPase KRas

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNitto Biopharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesNitto Biopharma Inc

Inactive CompaniesN/A

Active IndicationsPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A